시장보고서

상품코드

1553654

세계의 양극성 장애 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 약제 클래스별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 08월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

양극성 장애 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 양극성 장애 시장은 2024-2030년에 걸쳐 CAGR 2.7%로 성장하여 2030년에는 58억 7,000만 달러에 달할 것으로 예측되고 있습니다.

양극성 장애에 대한 인식을 높이기 위한 정부의 지원과 환자의 기분과 정신 상태의 정확한 검출을 용이하게 하는 기술의 진보는 이 시장의 성장을 가속하는 요인의 일부입니다.

양극성 장애의 유병률 증가는 예측 기간 동안 시장 성장을 가속할 것으로 보입니다. 정부의 이니셔티브도 시장 성장을 뒷받침합니다. 예를 들어, 국제양극성장애재단의 사회보장장애보험(SSDI) 또는 보충적 보장소득(SSI)은 양극성장애를 앓고 있는 사람들의 이익을 위해 사회보장청(미국)이 제공하는 프로그램입니다.

게다가 스마트폰, 스마트워치, 웨어러블 디바이스의 기술적 진보는 환자의 기분이나 정신상태를 검출하기 위해 생리학적, 행동학적, 환경적 데이터를 효과적으로 캡처함으로써 진단률을 향상시키고 있다 합니다. 또한 온라인 자가 관리 도구도 적시에 개입하여 결과적으로 이 질환의 진단률과 치료율이 향상됩니다. 그러나 이 시장에서 블록버스터 약물의 특허 해지는 예측 기간 동안 시장 역학에 영향을 미칠 것으로 보입니다. 또한, 양극성 장애의 치료로서 제네릭 의약품과의 격렬한 경쟁이 예상됩니다. 기타, 양극성 장애 치료에 따른 부작용이나 양극성 장애의 오진 등이 예측 기간 중 시장 성장을 억제하는 요인이 될 것 같습니다.

양극성 장애 시장 보고서 하이라이트

양극성 장애의 유병률 상승으로 기분 안정제 부문이 2023년 시장 점유율을 35.0%로 독점하고 있습니다.
2023년 시장은 선택적 세로토닌 재흡수 억제제 부문이 25.0%의 점유율을 차지했습니다. 시장 성장의 요인은 선택적 세로토닌 재 흡수 억제제(SSRI)의 효능과 안전성 프로파일이며 양극성 장애로 인한 우울증 증상 관리에 효과적입니다.
2023년에는 병원 약국 부문이 49.8%의 점유율을 차지하고 시장을 독점했습니다. 이 시장 성장은 정신 건강 진단을 요구하는 환자 수 증가로 인한 것입니다.
양극성 장애 시장은 북미가 2023년에 39.4%의 점유율을 차지했습니다. 이는 양극성 장애의 증례가 증가하고 이 지역에 중요한 의료기관이 존재하기 때문입니다.

양극성 장애 시장 점유율, 지역별, 2023년과 2030년, 100만 달러
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 프로파일
- Advanced Micro Devices
- AstraZeneca
- Eli Lilly and Company
- GSK plc
- Johnson &Johnson Services, Inc
- Pfizer Inc.
- AbbVie Inc.
- Otsuka Holdings Co., Ltd.
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Sumitomo Pharma America, Inc

JHS 24.10.10

Bipolar Disorder Market Growth & Trends:

The global bipolar disorder market is anticipated to reach USD 5.87 billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient's mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation's Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient's mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period. Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Bipolar Disorder Market Report Highlights:

The mood stabilizer segment dominated the market in 2023, with a share of 35.0% in 2023 due to the rising prevalence of bipolar disorder.
The selective serotonin reuptake inhibitor segment dominated the market in 2023, with a share of 25.0%. The factors responsible for the market growth are the efficacy and safety profile of selective serotonin reuptake inhibitors (SSRIs), which are effective in managing the depressive symptoms occurring due to bipolar disorder.
The hospital pharmacies segment dominated the market in 2023, with a share of 49.8% in 2023. This market growth was attributed to the increase in the number of patients seeking a diagnosis of their mental health.
North America dominated the bipolar disorder market with a market share of 39.4% in 2023. This was attributed to the increase in the cases of bipolar disorders and the presence of significant medical institutes in the region.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Bipolar Disorder Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Bipolar Disorder Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Bipolar Disorder Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Bipolar Disorder Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Mood Stabilizer
- 4.3.1. Mood Stabilizer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Anticonvulsants
- 4.4.1. Anticonvulsant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Antipsychotic Drugs
- 4.5.1. Antipsychotic Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Antidepressant Drugs
- 4.6.1. Antidepressant Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Antianxiety Drugs
- 4.7.1. Antianxiety Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Other Types
- 4.8.1. Other Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Bipolar Disorder Market: Drug Class Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Bipolar Disorder Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
5.3. Selective Serotonin Reuptake Inhibitor
- 5.3.1. Selective Serotonin Reuptake Inhibitor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Serotonin Norepinephrine Reuptake Inhibitor
- 5.4.1. Serotonin Norepinephrine Reuptake Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Tricyclic Antidepressant Drugs
- 5.5.1. Tricyclic Antidepressant Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Monoamine Oxidase Inhibitors
- 5.6.1. Monoamine Oxidase Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Benzodiazepines
- 5.7.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Beta Blockers
- 5.8.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Other Drugs Classes
- 5.9.1. Other Drugs Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Bipolar Disorder Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Bipolar Disorder Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacies
- 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
- 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Bipolar Disorder Market: Regional Estimates & Trend Analysis

7.1. Bipolar Disorder Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
- 7.2.1. North America Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. China Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Australia
  - 7.4.5.1. Australia Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. UAE Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Advanced Micro Devices
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. AstraZeneca
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Eli Lilly and Company
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. GSK plc
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Johnson & Johnson Services, Inc
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Pfizer Inc.
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. AbbVie Inc.
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Otsuka Holdings Co., Ltd.
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Bristol-Myers Squibb Company
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Teva Pharmaceutical Industries Ltd.
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.11. Sumitomo Pharma America, Inc
  - 8.4.11.1. Participant's Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Recent Developments/ Strategic Initiatives

세계의 양극성 장애 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 약제 클래스별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

양극성 장애 시장의 성장과 동향

양극성 장애 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 양극성 장애 시장의 변수, 동향, 범위

제4장 양극성 장해 시장 : 유형별, 추정·동향 분석

제5장 양극성 장해 시장 : 약제 클래스별, 추정·동향 분석

제6장 양극성 장해 시장 : 유통 채널별, 추정·동향 분석

제7장 양극성 장해 시장 : 지역별, 추정·동향 분석